home.social

#duchennemusculardystrophy — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #duchennemusculardystrophy, aggregated by home.social.

  1. Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

    CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…
    #NewsBeep #News #Medication #acuteliverfailure #ambulatorypatients #CA #Canada #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #sareptatherapeutics
    newsbeep.com/ca/283661/

  2. Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda

  3. Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda

  4. Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda

  5. Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda

  6. Thrilled to share our story on the first rationally designed #covalent #HDAC inhibitor! YSR734 uses an SNAr-reactive electrophile to engage a noncatalytic nitrosylation site cysteine in #HDAC2, showing in vitro activity in AML & #DuchenneMuscularDystrophy!
    pubs.acs.org/doi/10.1021/acs.j

  7. Thrilled to share our story on the first rationally designed #covalent #HDAC inhibitor! YSR734 uses an SNAr-reactive electrophile to engage a noncatalytic nitrosylation site cysteine in #HDAC2, showing in vitro activity in AML & #DuchenneMuscularDystrophy!
    pubs.acs.org/doi/10.1021/acs.j

  8. Thrilled to share our story on the first rationally designed #covalent #HDAC inhibitor! YSR734 uses an SNAr-reactive electrophile to engage a noncatalytic nitrosylation site cysteine in #HDAC2, showing in vitro activity in AML & #DuchenneMuscularDystrophy!
    pubs.acs.org/doi/10.1021/acs.j

  9. Thrilled to share our story on the first rationally designed #covalent #HDAC inhibitor! YSR734 uses an SNAr-reactive electrophile to engage a noncatalytic nitrosylation site cysteine in #HDAC2, showing in vitro activity in AML & #DuchenneMuscularDystrophy!
    pubs.acs.org/doi/10.1021/acs.j

  10. Data Support Placebo Group Alternatives in Rare Disease Trials

    Findings from a review of medical #data and #records indicate matched #genetic control groups may not be needed in clinical trials testing treatments for Duchenne muscular dystrophy.

    sciencebusiness.technewslit.co

    #News #Science #Business #ClinicalTrials #DuchenneMuscularDystrophy #Neuroscience #Neurology #ControlGroup #Placebo #Statistics #RareDisease #InheritedDisease #RealWorldData

  11. Data Support Placebo Group Alternatives in Rare Disease Trials

    Findings from a review of medical #data and #records indicate matched #genetic control groups may not be needed in clinical trials testing treatments for Duchenne muscular dystrophy.

    sciencebusiness.technewslit.co

    #News #Science #Business #ClinicalTrials #DuchenneMuscularDystrophy #Neuroscience #Neurology #ControlGroup #Placebo #Statistics #RareDisease #InheritedDisease #RealWorldData

  12. Data Support Placebo Group Alternatives in Rare Disease Trials

    Findings from a review of medical #data and #records indicate matched #genetic control groups may not be needed in clinical trials testing treatments for Duchenne muscular dystrophy.

    sciencebusiness.technewslit.co

    #News #Science #Business #ClinicalTrials #DuchenneMuscularDystrophy #Neuroscience #Neurology #ControlGroup #Placebo #Statistics #RareDisease #InheritedDisease #RealWorldData

  13. Data Support Placebo Group Alternatives in Rare Disease Trials

    Findings from a review of medical #data and #records indicate matched #genetic control groups may not be needed in clinical trials testing treatments for Duchenne muscular dystrophy.

    sciencebusiness.technewslit.co

    #News #Science #Business #ClinicalTrials #DuchenneMuscularDystrophy #Neuroscience #Neurology #ControlGroup #Placebo #Statistics #RareDisease #InheritedDisease #RealWorldData

  14. Huge thanks @ElectricWill for your wonderful donation 🙌🏻 to our fundraising campaign for #DuchenneMuscularDystrophy

    I’m really looking forward to connecting with you more on here!

    justgiving.com/fundraising/end

  15. Our family has a young friend with #DuchenneMuscularDystrophy. We fundraise to help find a cure, - currently believed to be imminent enough to save many thousands of lives.

    Each of my children has taken on a challenge to help. Last year, my 11 year-old walked the 102 mile #CotswoldWay. Thanks to people’s incredible generosity, he raised £10k for #DuchenneUK!

    I am so proud of him ❤️

    I would be so grateful if you could boost this to help us raise awareness. Thank you!

    *More info in ALT text*